VDDI Pharmaceuticals' business strategy is to in-license products
at an early stage of development and carry out development of the
VDDI Pharmaceuticals has an active in-licensing program, specifically
in the Infectious disease, oncology, and Cardiovascular fields.
It is seeking novel molecules and technologies complementary to
its existing programs.
The company out-licenses to corporate partners in a process consistent
with current licensing practices between biotechnology companies
and pharmaceutical marketing companies and will also participate
in co-development programs. Licensees are expected, to the extent
necessary, to participate in the remaining clinical development
required to obtain final regulatory approval for the products licensed.
All of the products in the VDDI Pharmaceuticals portfolio are available
for out-licensing and co-development proposals.
For licensing information contact Stephen Porter at info@VirtualDrugDevelopment.com.